Financials in USD. Standardized financial statements.
A compact view of how CaliPharms, Inc. turns revenue into operating income and net income.
| Metric | FY 2017 | FY 2016 | FY 2015 | FY 2013 |
|---|---|---|---|---|
| Revenue? | $12,000 | $0 | $0 | $0 |
| Revenue Growth? | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 |
| Gross Profit? | $12,000 | $0 | $0 | $0 |
| Gross Margin? | +100.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $1.36M | $357,861 | $340,276 | $184,184 |
| Operating Income? | -$1.35M | -$357,860 | -$340,280 | -$184,184 |
| EBITDA? | -$1.35M | -$357,860 | -$340,280 | -$184,184 |
| Income Before Tax | -$1.42M | -$441,586 | -$958,629 | -$213,249 |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income? | -$1.42M | -$441,586 | -$958,629 | -$213,249 |
| EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
| Diluted EPS? | $-0.00 | $-0.00 | $-0.00 | $-0.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality